NUWE

Nuwellis, Inc. (NUWE) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Nuwellis, Inc. is a medical device company focused on the Aquadex System for ultrafiltration therapy to treat fluid overload in patients unresponsive to diuretics. The company operates as a non-accelerated filer and smaller reporting company. As of November 8, 2024, there were 4,373,968 shares of common stock outstanding.

Key Financial Metrics

Note: Q3 2024 Net Income of $2.36M is primarily driven by a $3.88M non-cash gain from the change in fair value of warrant liability, offsetting an operating loss of $1.53M.

Material Changes vs. Prior Period

• Revenue: Q3 2024 net sales decreased 1.9% year-over-year due to lower circuit and console sales, partially offset by one-time SeaStar Medical sales. YTD sales increased 1.7%.
• Profitability: Gross margin improved significantly to 70.0% in Q3 2024 from 57.2% in Q3 2023, driven by higher manufacturing volumes and lower fixed overhead.
• Expenses: Operating expenses decreased substantially. Selling, General, and Administrative (SG&A) expenses fell 21.2% QoQ and 22.4% YTD. R&D expenses dropped 56.5% QoQ and 41.3% YTD due to reduced consulting and compensation costs.
• Capital Structure: The company executed a 1-for-35 reverse stock split effective June 27, 2024. Significant equity financings occurred in April, July, and August 2024, raising approximately $5.6M in gross proceeds.
• Warrant Liability: A $4.6M non-cash gain was recorded in the first nine months of 2024 due to the reclassification of certain warrants from liability to equity and changes in fair value.

Guidance, Outlook, and Risks

• Liquidity & Going Concern: The company has an accumulated deficit of $297.3M and raised substantial doubt about its ability to continue as a going concern. Management estimates existing capital resources will support operations through May 31, 2025. Additional capital raises are expected.
• Cost Reduction: Management implemented measures to reduce the monthly cash burn rate by approximately 40%, including job eliminations, salary reductions for senior management, and suspension of the 401(k) match (restored Oct 1, 2024).
• Recent Financing: On November 5, 2024, the company announced agreements for the immediate exercise of warrants for approximately $3.8M in gross proceeds, issuing new fixed-price warrants in exchange.
• Nasdaq Compliance: The company regained compliance with the Minimum Bid Price Requirement in July 2024. Nasdaq granted continued listing pending the filing of this 10-Q to demonstrate compliance with the Stockholder's Equity Requirement.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, citing two material weaknesses in financial reporting controls identified in the prior year.
• Legal/Partnerships: The company terminated its Supply Agreement with DaVita Inc. in August 2024. A settlement with SeaStar Medical was reached in October 2024 for $900,000, with $500,000 received and recognized in October.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.91M cash balance against the projected burn rate to confirm the May 2025 liquidity runway.
• Warrant Accounting: Review the reclassification of warrants from liability to equity and the impact of fair value changes on reported net income, as these are non-cash items.
• Nasdaq Status: Monitor future filings to ensure continued compliance with Nasdaq Stockholder's Equity requirements to avoid delisting.
• Internal Controls: Assess the remediation plan for the two material weaknesses in internal controls over financial reporting.
• Revenue Concentration: Note that for the nine months ended Sept 30, 2024, one customer represented 16% of net sales.